Sandeep Laumas
CIK: 0001721664
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (13 total)
- May 14, 2026UNCY
Unicycive Therapeutics, Inc.
Award(A)DirectRestricted Stock Units
47.9K shares- - May 14, 2026UNCY
Unicycive Therapeutics, Inc.
Award(A)DirectRestricted Stock Units
42.1K shares- - May 14, 2026UNCY
Unicycive Therapeutics, Inc.
Award(A)DirectRestricted Stock Units
84.2K shares- - May 14, 2026UNCY
Unicycive Therapeutics, Inc.
Award(A)DirectRestricted Stock Units
84.2K shares- - May 14, 2026UNCY
Unicycive Therapeutics, Inc.
Award(A)DirectRestricted Stock Units
42.1K shares- - Jan 9, 2026BTAI
BioXcel Therapeutics, Inc.
Award(A)DirectStock Option (Right to Buy)
17K shares- - Sep 10, 2025TIL
Instil Bio, Inc.
Sale(S)Direct17.5K shares at avg. $23.04$404K - Sep 10, 2025TIL
Instil Bio, Inc.
Exercise(M)Direct17K shares at avg. $11.60$197K - Sep 10, 2025TIL
Instil Bio, Inc.
Sale(S)Direct12.5K shares at avg. $23.88$298K - Sep 10, 2025TIL
Instil Bio, Inc.
Exercise(M)Direct13K shares at avg. $12.68$165K - Jul 28, 2025UNCY
Unicycive Therapeutics, Inc.
Award(A)DirectStock Options
21.2K shares- - Apr 25, 2025TIL
Instil Bio, Inc.
Award(A)DirectEmployee Stock Option (right to buy)
44.9K shares- - Sep 18, 2024TIL
Instil Bio, Inc.
Award(A)DirectEmployee Stock Option (right to buy)
45K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| May 14, 2026 |  UNCY Unicycive Therapeutics, Inc. | Award(A) Restricted Stock Units | 47,941 | - | - | Direct |
| May 14, 2026 | UNCY Unicycive Therapeutics, Inc. | Award(A) Restricted Stock Units | 42,100 | - | - | Direct |
| May 14, 2026 | UNCY Unicycive Therapeutics, Inc. | Award(A) Restricted Stock Units | 84,200 | - | - | Direct |
| May 14, 2026 | UNCY Unicycive Therapeutics, Inc. | Award(A) Restricted Stock Units | 84,200 | - | - | Direct |
| May 14, 2026 | UNCY Unicycive Therapeutics, Inc. | Award(A) Restricted Stock Units | 42,100 | - | - | Direct |
| Jan 9, 2026 |  BTAI BioXcel Therapeutics, Inc. | Award(A) Stock Option (Right to Buy) | 17,000 | - | - | Direct |
| Sep 10, 2025 |  TIL Instil Bio, Inc. | Sale(S) | 17,539 | $23.04 | $404,099 | Direct |
| Sep 10, 2025 | TIL Instil Bio, Inc. | Exercise(M) | 17,000 | $11.60 | $197,200 | Direct |
| Sep 10, 2025 | TIL Instil Bio, Inc. | Sale(S) | 12,461 | $23.88 | $297,569 | Direct |
| Sep 10, 2025 | TIL Instil Bio, Inc. | Exercise(M) | 13,000 | $12.68 | $164,840 | Direct |
| Jul 28, 2025 | UNCY Unicycive Therapeutics, Inc. | Award(A) Stock Options | 21,200 | - | - | Direct |
| Apr 25, 2025 | TIL Instil Bio, Inc. | Award(A) Employee Stock Option (right to buy) | 44,851 | - | - | Direct |
| Sep 18, 2024 | TIL Instil Bio, Inc. | Award(A) Employee Stock Option (right to buy) | 45,000 | - | - | Direct |
1-13 of 13 transactions
About Laumas Sandeep
Laumas Sandeep (SEC CIK 0001721664) files insider reports with the SEC as Director of Unicycive Therapeutics, Inc. (UNCY), Director of BioXcel Therapeutics, Inc. (BTAI) and CFO and CBO of Instil Bio, Inc. (TIL).
Signal8 holds 8 ownership filings by Laumas Sandeep, all Form 4s, filed between Sep 23, 2024 and Jul 28, 2026. Those filings report 13 transactions, from Sep 18, 2024 to May 14, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Laumas Sandeep's filings is in MOUNTAIN VIEW, CA.
Recent filings by Laumas Sandeep
- May 14, 2026: Grants or awards of UNCY derivative securities (5 lines, Form 4, code A).
- Jan 9, 2026: Grant or award of BTAI derivative securities (Form 4, code A).
- Sep 10, 2025: Open-market sale of TIL shares (Form 4, code S).
- Sep 10, 2025: Option exercise of TIL shares (Form 4, code M).
- Sep 10, 2025: Open-market sale of TIL shares (Form 4, code S).
Other insiders filing for Unicycive Therapeutics, Inc. (UNCY)
- Manning Meredith, Director
- Kenkare-Mitra Sara, Director
- Gupta Shalabh K., CEO
- Gupta Pramod, EVP, Pharmaceuticals and BD
- Townsend John, CFO
- Jermasek Douglas, EVP, Corporate Strategy